Abstract
Breast cancer remains a significant global health challenge, necessitating the discovery of precise molecular mechanisms to improve patient outcomes. This study integrates multi-platform bioinformatics—including Robust Rank Aggregation (RRA) and Weighted Gene Co-expression Network Analysis (WGCNA)—with RNA in situ detection to identify novel hub genes. While EZH2 was confirmed as a central regulator, four novel hub genes—CENPL, ISG20L2, LSM4, and MRPL3—were identified as being significantly upregulated in tumor tissues. These genes correlate with cancer progression and demonstrate high diagnostic and prognostic potential, serving as promising candidates for clinical biomarkers.
Introduction
Breast cancer is characterized by high heterogeneity, making consistent diagnosis and prognosis difficult across different patient populations. Previous studies often suffered from inter-study noise due to small, single-platform datasets. To address this, researchers utilized a robust computational pipeline to identify "hub genes"—highly connected nodes in biological networks that act as central regulators of disease progression. This study focuses on identifying and validating novel markers that can reliably distinguish tumor tissue and predict overall survival.
Methodology and Data Integration
The researchers employed a multi-staged approach to ensure the reliability of their findings:
- Robust Rank Aggregation (RRA): Integrated eight GEO datasets (e.g., GSE21422, GSE65194) to identify consistently differentially expressed genes while minimizing batch effects.
- WGCNA and PPI Networks: Weighted Gene Co-expression Network Analysis identified gene modules correlated with clinical traits, while Protein-Protein Interaction (PPI) networks identified the most connected "hubs" using nine topological algorithms.
- Validation Datasets: Performance was tested using TCGA-BRCA for diagnostics and METABRIC for prognostic validation and Gene Set Enrichment Analysis (GSEA).
- Experimental Verification: RNA in situ detection (rolling circle amplification) was used to visualize mRNA abundance at the single-cell level in breast cancer cell lines (MDA-MB-231, MCF7) versus normal controls (MCF10A).
Functional Convergence and Pathway Analysis
Functional enrichment analysis revealed that the identified hub genes are not merely passive markers but are actively involved in core oncogenic processes. The four novel genes (CENPL, ISG20L2, LSM4, MRPL3) are heavily enriched in pathways related to the cell cycle, nuclear division, and DNA replication.
As shown in the enrichment plots, these genes participate in critical biological processes (BP) such as mitotic nuclear division and regulation of the cell cycle. KEGG pathway analysis further linked these genes to broader cancer signaling, including the PI3K-Akt pathway and proteoglycans in cancer. Additionally, the study found an epigenetic link: high expression of these genes often correlates with DNA hypomethylation, suggesting that the loss of epigenetic "brakes" leads to their pathological overproduction.
Clinical Significance and Results
The study established strong evidence for the clinical utility of these four novel hub genes:
- Diagnostic Accuracy: In TCGA datasets, the Area Under the Curve (AUC) was remarkably high, with LSM4 (0.948) and CENPL (0.934) showing excellent sensitivity and specificity in distinguishing tumor from normal tissue.
- Prognostic Value: High expression levels of all four genes were significantly associated with poorer overall survival (OS). Kaplan-Meier analysis indicated a significantly higher hazard ratio (HR > 1) for patients with elevated levels of these markers.
- Clinicopathological Correlation: Increased expression was positively correlated with aggressive tumor traits, including higher SBR grades and lymph node metastasis.
Conclusion
By combining robust meta-analysis of transcriptomic data with single-cell imaging, this study identifies CENPL, ISG20L2, LSM4, and MRPL3 as a novel signature of hub genes in breast cancer. While these markers show immense promise for diagnostic and prognostic applications, further research is required to elucidate their exact biochemical mechanisms and validate their performance in prospective clinical trials.
Summary updated